Julio 2022: Según la investigación más reciente realizada por Emergen Research, el mercado mundial de la terapia con células T con CAR alcanzó un tamaño de 1.29 millones de dólares en 2021 y se espera que registre una tasa compuesta anual de ingresos del 24.9 por ciento en el transcurso del período de pronóstico. Se espera que la creciente incidencia del cáncer en todo el mundo, así como la creciente tasa de mortalidad causada por el cáncer, sean los principales impulsores del crecimiento de los ingresos en el mercado mundial de terapia con células CAR-T durante el período de pronóstico. La expansión de las actividades de ensayos clínicos a un ritmo vertiginoso, la proliferación de fusiones y adquisiciones y el atractivo de las ofertas públicas iniciales son factores que están contribuyendo al crecimiento de los ingresos en el mercado mundial de terapia de células T con CAR.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global Terapia de células T con CAR market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the Terapia de células T con CAR market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Hallazgos significativos adicionales del informe indican que
En 2021, el segmento de células B grandes difusas linfoma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with Terapia de células T con receptor de antígeno quimérico, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell linfomas no Hodgkin who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Las empresas clave que operan actualmente en el mercado se investigan más a fondo en este informe, al igual que sus perfiles de empresa, carteras de productos, estrategias de expansión y alianzas estratégicas. Algunos ejemplos de este tipo de alianzas incluyen fusiones y adquisiciones, colaboraciones y empresas conjuntas. Además de esto, proporciona aspectos destacados sobre los logros y la situación financiera de la empresa, así como información sobre el alcance del mercado y la posición global de la empresa.
Empresas destacadas en el mercado mundial Terapia de células T con CAR:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd. y Eli Lilly and Company .
Obtenga más información sobre el informe de mercado global Terapia de células T con CAR en: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
